The invention provides pharmaceutical and cosmetic compositions for application to skin showing elastic tissue changes comprising an enzymatic material having elastolytic activity and a vehicle.

Novel compositions for the treatment of IRDS and ARDS are indicated which contain N-(3,5-dichloro-pyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethox- ybenzamide and/or its pharmacologically tolerable salts and lung surfactant.

The present invention involves the novel use of various classes of drugs, such as H.sub.2 and H.sub.3 agonists, as erectogenic agents in the treatment of male and female sexual dysfunction.

A pharmaceutical composition for oral adminstration comprising a film-coated solid dosage form including 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide or a pharmaceutically acceptable salt or solvate thereof as active ingredient. The film-coated solid dosage forms are of use in the treatment of conditions associated with cephalic pain, in particular migraine.

Agricultural compositions comprising paraesthetic agrochemicals, such as pyrethroids, and an amount of urea effective to reduce the paraesthetic effect of such agrochemicals.

A skin- or hair-care composition containing silica additionally comprises a C.sub.2-4 alkyl ester of a di, tri- or tetrabasic carboxylic acid or hydroxy-carboxylic acid (optionally acetylated). The alkyl ester may be dissolved in an aqueous solvent system.

The problem of providing a storage stable anti-calculus toothpaste comprising a tripolyphosphate salt is remedied by incorporating more than 4% of the salt and having the pH from about 8 to about 10. A tripolyphosphate salt may also be combined with a noncationic anti-bacterial agent such as triclosan to provide a composition having anti-calculus and anti-plaque activity.

The present invention involves the novel use of H.sub.2 and H.sub.3 agonists, as erectogenic agents in the treatment of male and female sexual dysfunction in an animal, including humans. The H.sub.2 and H.sub.3 agonists may be administered by intracavernousm injection, topically, transdermally, or intraurethrally. The method of use may also include a second therapeutic agent which either facilitates, potentiates or is erectogenic. The second agent may be administered sequentially or contemporane...

An aqueous composition for the preparation of optically clear products for use in human or animal healthcare comprising 0.1 to 2.0% w/w of an oil-soluble ingredient as a 20-30% w/w dispersion in a suitable oil or 0.1 to 5.0% w/v as the pure crystalline compound, 2-20% of an emulsifier having an HLB (hydrophilic/lipophilic balance) value of between 10 and 18 or where a blend of emulsifiers is employed, a calculated HLB value of between 10 and 18 and 0.1 to 1.0% of an antioxidant or a mixture of a...

A transparent liquid dentifrice which comprises a particulate silica abrasive material present in from 10 to 15% by weight of the composition, stably suspended in an aqueous liquid vehicle with the aid of a suspending agent; and a humectant system which consists essentially of sorbitol, present in from 50 to 55% by weight of the composition (measured as the 100% active), and polyethylene glycol with average molecular weight in the range 200 to 600, present in from 0.5 to 3% by weight of the comp...